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4S = Scandinavian Simvastatin Survival Study; DAIS = Diabetes Atherosclerosis Intervention Study; FIELD = Fenofibrate Intervention and Event
Lowering in Diabetes; VA-HIT = Veterans Administration High Density Lipoprotein Intervention Trial.
CHD = coronary heart disease; HDL = high-density lipoprotein; LDL = low-density lipoprotein.
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There is a worldwide epidemic of type 2 diabetes that is
contributing to a disturbing increase in the incidence of
coronary heart disease (CHD) in many countries. The precise
mechanisms by which type 2 diabetes causes CHD is
uncertain, although the dyslipidaemia that is common in this
form of diabetes almost certainly has a role. Indeed, several
large-scale intervention studies with lipid-modifying therapy
have included a sufficient number of type 2 diabetics to be
able to conclude that, as in non-diabetics, treatment of the
abnormal lipids in type 2 diabetes reduces future coronary
risk. These studies have used both statins [1–3] and fibrates
[4,5] as the therapeutic intervention.
Intervention studies that have included type 2
diabetics
Statin trials
The Scandinavian Simvastatin Survival Study (4S) [1] was a
secondary prevention study that included 201 patients with
type 2 diabetes. The diabetics in the active treatment group
had a 55% decrease in future coronary events (P = 0.002).
The Cholesterol and Recurrent Events (CARE) trial included
603 diabetic subjects [2]. Coronary event reduction in the
diabetics on pravastatin was 25% (P = 0.05). In the Long-
Term Intervention with Pravastatin in Ischaemic Disease
(LIPID) Study [3], another secondary prevention trial, there
were 782 type 2 diabetics. In this study, active treatment with
pravastatin reduced coronary events in the diabetics by 19%
(not significant).
Fibrate trials
The Helsinki Heart Study [4] was a primary prevention trial
using gemfibrozil as the active agent. There were 135
subjects with type 2 diabetes in whom active treatment
reduced adverse coronary events by 68%, although because
of the small sample size, this result was not statistically
significant. The Veterans Administration High Density
Lipoprotein Intervention Trial (VA-HIT) [5] also used
gemfibrozil as the active agent in subjects with existing CHD.
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Abstract
Type 2 diabetes is an increasing cause of premature coronary heart disease. Several trials with lipid-
modifying therapy have included sufficient numbers of diabetics to indicate that treatment of diabetic
dyslipidaemia with either fibrates or statins reduces the risk of future coronary events in such patients.
However, until recently no reported study had been designed specifically to investigate the effects of
intervening in patients with type 2 diabetes. The Diabetes Atherosclerosis Intervention Study (DAIS) is
an angiographic study in which 418 diabetic subjects were randomized to micronised fenofibrate or
placebo groups. After 3 years of treatment, the fenofibrate group had a significantly reduced rate of
progression of coronary atherosclerosis. This study, when considered with the results of other studies
that have included diabetics, has important implications for the treatment of diabetic dyslipidaemia. The
evidence that is currently available supports a place for both fibrates and statins, either as
monotherapy or in combination, in the treatment of diabetic dyslipidaemia.
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In this study there were 627 type 2 diabetics in whom
gemfibrozil reduced future coronary events by 24%
(P = 0.05).
Until recently, no reported study had been conducted
exclusively in patients with type 2 diabetes. It is therefore of
great interest to see the results of the Diabetes
Atherosclerosis Intervention Study (DAIS), which have
recently been published [6].
Diabetes Atherosclerosis Intervention Study
DAIS included 418 men and women with type 2 diabetes
who were randomised to receive micronised fenofibrate
(200 mg/day), or placebo, and followed for 3 years. Half of
the participants had previous clinical coronary heart disease
but all had at least one lesion visible on coronary
angiography. In this angiographic study, the primary
endpoints were changes in minimum lumen diameter, mean
segment diameter, and mean percentage stenosis.
The baseline lipid profiles of the active treatment and placebo
groups were well matched and were typical of reported
profiles in type 2 diabetes. Glycaemic control was
acceptable by recognized standrads throughout the study in
both groups. Fenofibrate had predictable effects on the
plasma lipids, with moderate but significant decreases in
total and low-density lipoprotein (LDL) cholesterol, a more
substantial and significant decrease in plasma triacylglycerol,
and a significant increase in high-density lipoprotein (HDL)
cholesterol. In terms of the primary endpoints, the fenofibrate
group had a 40% reduction in progression of angiographic
changes as judged by minimum lumen diameter (P = 0.029),
42% less progression as judged by changes in percentage
diameter stenosis (P = 0.02), and 25% less progression in
mean segment diameter (P = 0.171, not significant).
Because of the relatively small numbers of participants in a
trial lasting 3 years, clinical events were not primary endpoints.
It was therefore predictable that differences in clinical
endpoints between the fenofibrate and placebo groups were
not statistically significant. However, it was encouraging to
note that when considering a composite clinical endpoint
(death, myocardial infarction, coronary angioplasty, coronary
bypass surgery, and hospitalisation for angina) there were 38
events in the fenofibrate group compared with 50 in the
placebo group. Although not statistically significant, the
magnitude of the decrease in clinical events was similar to
that observed in the diabetics in other trials.
Comparison of DAIS with other angiographic
studies
Overall, the reduction in progression of angiographic
changes observed in the fenofibrate group in DAIS is of the
same order as reported for non-diabetics treated with other
agents in several trials [7–9]. Previous studies of this type in
diabetics have not been reported.
Implications of DAIS
The typical dyslipidaemia in type 2 diabetes is a moderate
increase in plasma triacylglycerol, a decrease in HDL
cholesterol and a total LDL cholesterol that is normal or
mildly elevated. Fenofibrate has been reported to decrease
plasma triacylglycerol and increase HDL cholesterol and, in
contrast with some other fibrates, also promotes a modest
decrease in LDL cholesterol. It can therefore be argued that
such an agent might be an appropriate therapy for type 2
diabetics. The results of DAIS add support to this view by
clearly demonstrating a slowing of coronary atherosclerosis
during 3 years of treatment with fenofibrate. The results are
also most encouraging with regard to the possible outcomes
in continuing, long-term, hard-endpoint trials using fenofibrate
in type 2 diabetics.
One of these is the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) study, in which more than
9000 type 2 diabetics have been randomised, double blind
to placebo or micronised fenofibrate. This 5-year study in
which the primary endpoint is coronary mortality is due to be
completed in 2004/2005. The FIELD study will provide a
clear answer to the role of fenofibrate in the prevention of
CHD in diabetes. The results of DAIS greatly strengthen the
justification for conducting the FIELD Study.
Statins and fibrates in the treatment of
diabetic dyslipiaemia
Considering the evidence from large-scale hard endpoint
trials that have included diabetics, and the recent evidence
from DAIS, it is apparent that treatment with both fibrates
and statins has the capacity to slow the progression of
coronary atherosclerosis and to reduce the future incidence
of coronary events. A question that frequently arises is:
Should we use a statin or a fibrate as the agent of first choice
to treat the dyslipidaemia in type 2 diabetes? On the basis of
current evidence, it is difficult to give a categorical answer.
However, it is possible to interpret the existing evidence as
supporting a case for using each class of drug.
There are two circumstances in which the choice of drug is
reasonably clear. In a diabetic with elevated LDL cholesterol,
the evidence from 4S [1] supports the use of a statin as the
drug of first choice. In contrast, if the LDL level is low in a lipid
profile characterized by a low HDL cholesterol and elevated
triacylglycerol, the evidence from VA-HIT [5] supports the use
of a fibrate as the agent of first choice. However, there is a
substantial group of type 2 diabetics in whom the levels of
both plasma triacylglycerol and LDL cholesterol are higher
than desirable and with low HDL cholesterol. Treatment with a
statin will undoubtedly correct the LDL cholesterol but might
leave the HDL low. Treatment with a fibrate might correct the
HDL cholesterol/triacylglycerol abnormality but might be
unable to lower LDL cholesterol to recommended target levels
for diabetics. In such cases, many physicians will opt to use
combination therapy with a statin and a fibrate. However, itCurrent Controlled Trials in Cardiovascular Medicine    October 2001 Vol 2 No 5 Barter
should also be noted that there is still no long-term evidence
on the safety or effectiveness of this combination. Therefore,
as potentially serious adverse effects might occasionally occur
when combining a fibrate and statin, this combination should
be offered only to patients who are at high coronary risk.
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